Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2017-003473-34-PT
EUCTR2017-003473-34-PTActive, not recruitingPhase 1

Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity who have reached target dose during run-in period

ovo Nordisk A/S0 sites902 target enrollmentStarted: February 27, 2018Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
902
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. Male or female, age = 18 years at the time of signing informed consent
  • •2. BMI = 30 kg/sqm or = 27 kg/sqm with the presence of at least one of the following weightrelated comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease
  • •3. History of at least one self-reported unsuccessful dietary effort to lose body weight
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 720
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 180

Exclusion Criteria

  • •1. HbA1c = 48 mmol/mol (6.5%) as measured by central laboratory at screening
  • •2. A self-reported change in body weight > 5 kg (11 lbs) within 90 days before screening
  • •irrespective of medical records

Investigators

Similar Trials

Active, not recruiting
Phase 1
Research study investigating how well semaglutide works in people suffering from overweight or obesityMedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersObesity
EUCTR2017-003473-34-NLovo Nordisk A/S900
Active, not recruiting
Phase 1
Research study investigating how well semaglutide works in people suffering from overweight or obesityObesity
EUCTR2017-003473-34-FRovo Nordisk A/S900
Active, not recruiting
Phase 1
Research study investigating how well semaglutide works in people suffering from overweight or obesityObesity
EUCTR2017-003436-36-PLovo Nordisk A/S1,950
Active, not recruiting
Phase 1
Research study investigating how well semaglutide works in people suffering from overweight or obesityMedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersObesity
EUCTR2017-003473-34-SEovo Nordisk A/S900
Active, not recruiting
Phase 1
Research study investigating how well semaglutide works in people with type 2 diabetes suffering from overweight or obesity1. Obesity2. Diabetes Mellitus, Type 2MedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2017-003414-10-ESovo Nordisk A/S1,200